T-CURX is the small-medium-sized-enterprise (SME) partner and benficiary in a € 6.1 M Horizon2020 grant awarded to the CARAMBA consortium of 11 European partners from 6 European countries
Today, T-CURX announces that the company is a beneficiary and SME partner in a € 6.1 M Horizon2020 5-year grant, called CARAMBA awarded to a consortium of 11 European partners from 6 European countries, which aims at developing a novel CAR-T cell product generated by non-viral gene transfer and using Sleeping Beauty transposon technology.
The autologous CAR-T cell product manufactured by innovative, virus-free Sleeping Beauty transposon technology is targeting SLAM-F7 (also known as CS1).
During the course of the 5-year Horizon-2020 funding period, the CARAMBA consortium plans to develop this novel SLAM-F7/CS-1 CAR-T product up to the stage of FiH (first-in-human) clinical trials in European patients suffering from Multiple Myeloma, in order to generate a first clinical proof-of-concept of the applicability of this innovative Sleeping Beauty-based non-viral CAR-T manufacturing platform and also for CAR-T cells targeting SLAM-F7/CS-1. The 5-year grant runs from January 2018 to December 2022, and T-CURX is in the leading position for the commercial translation of results from the SLAM-F7/CS-1 clinical trial after the end of the grant-funded period.